Aspirin resistance, platelet turnover, and diabetic angiopathy: A 2011 update

Thrombosis Research

Volumn 129, Issue 3, 2012, Pages 341-344

  Di Minno, Matteo Nicola Dario ^a   Lupoli, Roberta ^a   Palmieri, Nicola MacArone ^a   Russolillo, Anna ^a   Buonauro, Agostino ^a   Di Minno, Giovanni ^a  

^a Department of Clinical Experimental Medicine   (Italy)

Author keywords

aspirin resistance; diabetic angiopathy; mouse anti thrombotic assay; pairs of aggregating agents; platelet turnover; stored platelets

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE;

ACUTE CORONARY SYNDROME; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFICACY; ENZYME ACTIVITY; HEART INFARCTION; ISCHEMIA; LOW DRUG DOSE; PLATELET TURNOVER; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STROKE; THROMBOCYTE; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ANIMALS; ASPIRIN; BLOOD PLATELETS; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TREATMENT FAILURE;

EID: 84857792897     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.11.020     Document Type: Review

References (50)

1. G. Di Minno, M.J. Murphy, and S. Silver Stored human platelets full aggregation potential in response to pairs of aggregating agents Blood 59 3 1982 563 568 (Pubitemid 12187475)
2. J.A. Grant, and M.C. Scrutton Positive interaction between agonists in the aggregation response of human blood platelets: interaction between ADP, adrenaline and vasopressin Br J Haematol 44 1 1980 109e12
3. G. Di Minno, and M.J. Silver Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol J Pharmacol Exp Ther 225 1 1983 57e60
4. G. Di Minno, M.J. Silver, and S. Murphy Monitoring the entry of new platelets into the circulation after ingestion of aspirin Blood 61 6 1983 1081e5
5. G. de Gaetano, C. Cerletti, E. Dejana, and R. Latini Pharmacology of platelet inhibition in humans: implications of the salicylateaspirin interaction Circulation 72 6 1985 1185e93
6. J.R. O'Brien Effects of salicylates on human platelets Lancet 1(7546 1968 779e83
7. E. Dejana, B. Barbieri, C. Cerletti, M. Livio, and G. de Gaetano Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats Br J Haematol 46 3 1980 Nov 465 469 (Pubitemid 11226411)
8. G.H. Rao, and J.G. White Epinephrine potentiation of arachidonateinduced aggregation of cyclooxygenase-deficient platelets Am J Hematol 11 1981 355
9. D. Tschoepe, P. Roesen, J. Esser, B. Schwippert, H.K. Nieuwenhuis, and B. Kehrel Large platelets circulate in an activated state in diabetes mellitus Semin Thromb Hemost 17 1991 433 438
10. E.C. van Pampus, P.C. Huijgens, A. Zevenbergen, H. Twaalfhoven, G.J. van Kamp, and M.M. Langenhuijsen Influence of aspirin on human megakaryocyte prostaglandin synthesis Eur J Haematol 50 1993 264 268 (Pubitemid 23224507)
11. P.D. Winocour Platelet turnover in advanced diabetes Eur J Clin Invest 24 Suppl. 1 1994 34 37 (Pubitemid 24223519)
12. G. Di Minno, M.J. Silver, A.M. Cerbone, and S. Murphy Trial of repeated low-dose aspirin in diabetic angiopathy Blood 68 4 1986 886e91
13. G. de Gaetano, and C. Cerletti Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 1 2003 2048e50
14. M.K. Halushka, and P.V. Halushka Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 108 2002 1620e2
15. C. Patrono Aspirin resistance: definition, mechanisms and clinical read-outs J Thromb Haemost 1 2003 1710e3
16. J.A. Cambria-Kiely, and P.J. Gandhi Aspirin resistance and genetic polymorphisms J Thromb Thrombolysis 14 2002 51e8
17. M.K. Halushka, L.P. Walker, and P.V. Halushka Genetic variation in cyclooxygenase 1: effects on response to aspirin Clin Pharmacol Ther 73 2003 122e30
18. F.M. Pulcinelli, P. Pignatelli, A. Celestini, S. Riondino, P.P. Gazzaniga, and F. Violi Inhibition of platelet aggregation by aspirin progressively decrease in long-term treated patients J Am Coll Cardiol 43 2004 1122e6
19. G. Di Minno Aspirin resistance and platelet turnover: A 25-year old issue Nutr Metab Cardiovasc Dis 21 8 2011 542 545
20. D.J. Angiolillo Variability in responsiveness to oral antiplatelet therapy Am J Cardiol 103 2009 27A 34A Suppl.
21. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance"and risk of cardiovascular morbidity: a systematic review and meta-analysis BMJ 336 2008 195 198 (Pubitemid 351212675)
22. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961e5
23. M. Crescente, A. Di Castelnuovo, L. Iacoviello, G. de Gaetano, and C. Cerletti PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients Thromb Haemost 99 6 2008 Jun 1129 1131 (Pubitemid 351810502)
24. M. Heras, H. Bueno, A. Bardají, A. Fernández-Ortiz, H. Martí, and J. Marrugat DESCARTES Investigators. Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry Heart 92 2006 1571 1576 (Pubitemid 44629158)
25. W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, and A. Budaj Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 30 2009 426 435
26. T.K. Schramm, G.H. Gislason, L. Køber, S. Rasmussen, J.N. Rasmussen, and S.Z. Abildstrøm Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people Circulation 117 2008 1945 1954 (Pubitemid 351543470)
27. A. Singla, M.J. Antonino, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 158 5 2009 784.e1-6
28. J. DiChiara, K.P. Bliden, U.S. Tantry, M.S. Hamed, M.J. Antonino, and T.A. Suarez The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019 (Pubitemid 350223637)
29. M.N. Di Minno, A. Guida, M. Camera, S. Colli, G. Di Minno, and E. Tremoli Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention Ann Med 43 7 2011 531 544
30. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650e5
31. P. Ferroni, S. Basili, and A. Falco DavI' G. Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 2004 1282 1291 (Pubitemid 40186123)
32. G. DavI', I. Catalano, M. Averna, A. Notarbartolo, A. Strano, and G. Ciabattoni Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 322 1990 1769 1774 (Pubitemid 20194655)
33. Antithrombotic Trialists' (ATT) Collaboration C. Baigent, L. Blackwell, R. Collins, J. Emberson, and J. Godwin Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
34. A.O. Maree, R.J. Curtin, A. Chubb, C. Dolan, D. Cox, and J. O'Brien Cycloxygenase-1 haplotype modulates platelet response to aspirin J Thromb Haemost 3 2005 2340 2345 (Pubitemid 41727215)
35. B. Rocca, P. Secchiero, G. Ciabattoni, F.O. Ranelletti, L. Catani, and L. Guidotti Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634e9
36. A.A. Weber, K.C. Zimmermann, J. Meyer-Kirchrath, and K. Schror Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance Lancet 353 1999 900 (Pubitemid 29126885)
37. C. Watala, M. Boncler, and P. Gresner Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus Pharmacol Rep 57 Suppl 2005 S42 S58
38. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442 (Pubitemid 32747607)
39. G. Di Minno, and F. Violi Aspirin resistance and diabetic angiopathy: back to the future Thromb Res 113 2004 97 99 (Pubitemid 38534486)
40. C. Watala, J. Pluta, J. Golanski, M. Rozalski, M. Czyz, and Z. Trojanowski Increased protein glycation in diabetes mellitus is associated with decreased aspirin- mediated protein acetylation and reduced sensitivity of blood platelets to aspirin J Mol Med 83 2005 148 158 (Pubitemid 40379303)
41. P.Y. Lee, W.H. Chen, W. Ng, X. Cheng, J.Y. Kwok, and H.F. Tse Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Am J Med 118 2005 723e7
42. F. Santilli, L. Mucci, and G. Davì TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus Intern Emerg Med 6 2011 203 212
43. S. Coccheri Antiplatelet drugs-do we need new options? With a reappraisal of direct thromboxane inhibitors Drugs 70 7 2010 887e908.
44. E.L. Grove, A.M. Hvas, S.B. Mortensen, S.B. Larsen, and S.D. Kristensen Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease J Thromb Haemost 9 2011 185e91
45. Würtz M, Wulff LN, Grove EL, Kristensen SD, Hvas AM. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res 2011 Aug 10 [Electronic publication ahead of print].
46. C. Cerletti, M.R. Carriero, and G. de Gaetano Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin N Engl J Med 314 5 1986 316e8
47. Russolillo A, Di Minno MN, Tufano A, Prisco D, Di Minno G. Filling the gap between science & clinical practice: Prevention of stroke recurrence. Thromb Res 2011 Sep 8 [Electronic publication ahead of print].
48. M.N. Di Minno, A. Russolillo, M. Camera, M. Brambilla, A. De Gregorio, E. Tremoli, and G. Di Minno New anti-thrombotic drugs for stroke prevention Curr Vasc Pharmacol 9 6 2011 723 732
49. G.A. Fitzgerald Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists Am J Cardiol 68 1991 5Be11B
50. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration Br Med J 296 6618 1988 320e31 (Clin Res Ed)